Disc Medicine received a Complete Response Letter from the FDA on February 13, 2026, rejecting its new drug application for bitopertin due to uncertainties requiring more evidence. This news caused the company's stock to fall 22% the same day. The Rosen Law Firm is investigating potential securities claims and preparing a class action lawsuit to recover investor losses for those who purchased Disc Medicine securities. Investors may join the class action without upfront fees through a contingency arrangement.
Bitcoin surged 22.1% last week, reaching near $77,364 and briefly testing $80,000, boosted by U.S. Treasury liquidity support and strong ETF inflows. Investors now await critical U.S. data releases on July inflation and Q2 GDP, plus Federal Reserve C...
FIS Senior VP Jakob Harrison highlights that the rapid pace of technological and consumer changes is reshaping the payments industry. Instead of focusing on single big events, he sees gradual shifts driven by multiple smaller developments. FIS is adv...
Zoom Communications is positioned for a significant stock rally, driven by a multi-year rounding bottom pattern and upcoming Q2 earnings. A key catalyst is its 0.3% stake in AI company Anthropic, whose IPO could value Zoom's holding between $3 billio...
The PUMP token from Pump.fun has surged 84% over the past week, reaching $0.005136, while the broader crypto market declined by 1.9%. This rally is driven by the platform's active buyback program, which has spent over $1 million daily repurchasing to...
The Eaton Vance Tax-Advantaged Dividend Income Fund (EVT) is currently not recommended as a buy because its discount has tightened to about 6% and its yield is near 6.8%, both less appealing than in recent years. The fund's income depends more on cap...
